What is Fidabio?
Fida Biosystems develops advanced analytical platforms based on its proprietary Flow Induced Dispersion Analysis (FIDA) technology. This innovation enables rapid and precise analysis of biomolecules and nanoparticles directly in complex biological samples, helping biotech and pharmaceutical companies better understand molecular behavior and accelerate drug development. The company's focus on cutting-edge analytical solutions positions it as a key player in the life sciences sector, supporting critical research and development initiatives.
How much funding has Fidabio raised?
Fidabio has raised a total of $5.9M across 1 funding round:
Series A
$5.9M
Series A (2025): $5.9M with participation from Fhraeus Startup and Growth and Danish Export and Investment Fund
Key Investors in Fidabio
Fhraeus Startup and Growth
Fhraeus Startup and Growth is a venture capital fund that specializes in supporting early-stage startups in the life science and technology sectors. The firm leverages its extensive experience in entrepreneurship to back innovative ventures focused on groundbreaking solutions in diagnostics and pharmaceuticals.
Danish Export and Investment Fund
Danish Export and Investment Fund is a company that operates in the State industry, headquartered in Copenhagen, Denmark. It employs 500 to 999 people and has a revenue between $25M to $50M.
What's next for Fidabio?
With this major enterprise-level funding, Fidabio is poised for significant expansion and further development of its FIDA technology. The strategic investment will likely fuel advancements in its analytical platforms, enabling broader applications within the biotech and pharmaceutical industries. This capital will support scaling operations, enhancing research capabilities, and potentially exploring new market segments to accelerate drug discovery and development processes for its clients.
See full Fidabio company page
